<DOC>
	<DOCNO>NCT00607763</DOCNO>
	<brief_summary>Infants toddler fungal infection receive 10 14 day treatment antifungal drug . Safety drug blood level assess</brief_summary>
	<brief_title>Study Mycamine® Infants Toddlers With Fungal Infections Evaluate Safety Blood Levels Drug</brief_title>
	<detailed_description>This prospective , multicenter , open-label , repeat-dose study . Subjects receive treatment intravenous micafungin 10 14 day ( per investigator clinical judgment ) daily dose 4.5 mg/kg ( determine subject 's weight baseline ) . Serial blood sample assessment pharmacokinetics collect .</detailed_description>
	<mesh_term>Candidiasis</mesh_term>
	<mesh_term>Candidemia</mesh_term>
	<mesh_term>Candidiasis , Invasive</mesh_term>
	<mesh_term>Micafungin</mesh_term>
	<mesh_term>Echinocandins</mesh_term>
	<criteria>1 . Subject ≥4 month &lt; 24 month 2 . Subject suspect , proven probable candidiasis , candidemia invasive candidiasis 3 . Subject sufficient venous access permit administration study medication , collection pharmacokinetic sample , monitor laboratory safety variables 1 . Subject evidence significant liver disease , define aspartate transaminase ( AST ) , alanine transaminase ( ALT ) , bilirubin alkaline phosphatase &gt; 5 time upper limit normal ( ULN ) 2 . Subject concomitant medical condition opinion investigator and/or medical monitor precludes enrollment study 3 . Subject history anaphylaxis , hypersensitivity , serious reaction echinocandin class antifungal 4 . Subject receive treatment echinocandin within one week prior first dose 5 . Subject status unstable subject unlikely complete study require procedure</criteria>
	<gender>All</gender>
	<minimum_age>4 Months</minimum_age>
	<maximum_age>23 Months</maximum_age>
	<verification_date>August 2014</verification_date>
	<keyword>Antifungal</keyword>
	<keyword>Echinocandin</keyword>
	<keyword>Candidiasis</keyword>
	<keyword>Micafungin</keyword>
</DOC>